Latest Us Market News

LTR Pharma has successfully completed the extractables study for its intranasal erectile dysfunction spray SPONTAN, confirming safety compliance and initiating the next phase of leachables testing to support FDA approval.

Orthocell has marked a pivotal milestone with the first US surgical use of its Remplir™ nerve repair device following FDA clearance, setting the stage for commercial expansion in a $1.6 billion market.

Reece Limited projects FY25 EBIT between A$548m and A$558m, citing ongoing softness in housing markets across Australia, New Zealand, and the US, alongside rising competition in its key US residential construction segment.

Ricegrowers Limited (SunRice) reported a 3.7% rise in profit after tax for FY25 despite a 1.5% decline in revenue, driven by strategic cost savings and product innovation. The company announced a fully franked 50 cent final dividend and reactivated its Dividend Reinvestment Plan.

Firebrick Pharma has raised $0.2 million in a placement well below its $1.6 million target, prompting a review of its expansion and product development plans for Nasodine.

Xero has completed a significant A$1.85 billion institutional placement to fund its acquisition of Melio, aiming to enhance its accounting and payments platform in the US market. A complementary A$200 million Share Purchase Plan will offer retail investors a chance to participate.

Evion Group’s joint venture in India has secured a significant first shipment of expandable graphite to a leading US company, marking a strategic foothold in the critical minerals supply chain outside China.

archTIS Limited addresses ASX concerns over a sharp rise in its share price, linking the movement to recent contract wins in major defence markets and ongoing acquisition talks in the US.

Amaero has completed commissioning its second advanced atomizer at its Tennessee facility, reinforcing its production capacity and reaffirming strong revenue visibility for FY2026. The company’s strategic investments position it as a key domestic supplier in the US advanced manufacturing sector.

Optiscan Imaging Ltd has entered a five-year exclusive collaboration with Long Grove Pharmaceuticals to jointly develop new clinical applications for the fluorescein drug AK-FLOUR®, supporting US clinical trials and FDA regulatory submissions for Optiscan’s InVue® surgical device.

Proteomics International has launched PromarkerD, a pioneering blood test that predicts diabetic kidney disease years before symptoms, marking its entry into the vast US healthcare market.

Mach7 Technologies has expanded its partnership with a major US radiology marketplace, signing a five-year licence amendment worth A$5 million that extends the contract by three years and adds significant value.